Get the Stockscreener App
17.96
3.03%
-0.55
Viridian Therapeutics Inc stock is traded at $17.96, with a volume of 411.53K.
It is down -3.03% in the last 24 hours and down -14.16% over the past month.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.
See More
Previous Close:
$18.51
Open:
$18.49
24h Volume:
411.53K
Relative Volume:
0.31
Market Cap:
$1.47B
Revenue:
$288.00K
Net Income/Loss:
$-228.06M
P/E Ratio:
-4.2259
EPS:
-4.25
Net Cash Flow:
$-168.82M
1W Performance:
-7.38%
1M Performance:
-14.16%
6M Performance:
+16.56%
1Y Performance:
+1.18%
1-Day Range:
$17.93
$18.65
1-Week Range:
$17.93
$20.11
52-Week Range:
$11.40
$27.20
Viridian Therapeutics Inc Stock (VRDN) Company Profile
Name
Viridian Therapeutics Inc
Sector
Industry
Phone
617.272.4600
Address
221 CRESCENT STREET, WALTHAM
Compare VRDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRDN
Viridian Therapeutics Inc
|
17.96 | 1.47B | 288.00K | -228.06M | -168.82M | -4.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.20 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.22 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.51 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.25 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Viridian Therapeutics Inc Stock (VRDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-19-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-25-24 | Initiated | TD Cowen | Buy |
| Sep-11-24 | Reiterated | Needham | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| May-09-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-09-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-14-23 | Initiated | BTIG Research | Buy |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| May-30-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-17-23 | Initiated | Wells Fargo | Overweight |
| Mar-30-23 | Initiated | Stifel | Buy |
| Dec-19-22 | Initiated | Cowen | Outperform |
| Dec-19-22 | Initiated | Needham | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Dec-01-22 | Initiated | H.C. Wainwright | Buy |
| Jun-23-22 | Initiated | B. Riley Securities | Buy |
| Nov-18-21 | Initiated | SVB Leerink | Outperform |
| Oct-12-21 | Initiated | Evercore ISI | Outperform |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Viridian Therapeutics Inc Stock (VRDN) Latest News
VRDN Stock Sees Decline of Approximately -7.82% in Last Five Days - Knox Daily
Viridian Therapeutics (NASDAQ:VRDN) Shares Down 5.8%What's Next? - MarketBeat
Viridian's Strategic Expansion: 527,750 Share Options Awarded as TED Programs Advance - StockTitan
Analyzing Ratios: Viridian Therapeutics Inc (VRDN)’s Financial Story Unveiled - The Dwinnex
Viridian Therapeutics Inc (VRDN)’s highs and lows: A closer look at its stock price fluctuations - US Post News
This trade activity should not be overlooked: Viridian Therapeutics Inc (VRDN) - SETE News
Wells Fargo Downgrades Viridian Therapeutics Inc (VRDN) to an Equal weight from an Overweight - Knox Daily
SG Americas Securities LLC Purchases 14,644 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Sees Significant Growth in Short Interest - MarketBeat
Moody Aldrich Partners LLC Acquires New Shares in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Brokers Set Expectations for VRDN Q1 Earnings - MarketBeat
FY2029 Earnings Estimate for VRDN Issued By Leerink Partnrs - MarketBeat
SG Americas Securities LLC Has $596,000 Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Viridian Therapeutics Stock Hits 3-Week High, Retail Buzz Builds On Chronic Thyroid Eye Disease Trial Data - MSN
Equities Analysts Offer Predictions for VRDN Q1 Earnings - Defense World
Graves Ophthalmopathy Market to Expand Significantly by 2034, States DelveInsight Report | Novartis, AdvanceCor, Apitope, Worg Pharma, AV7 Limited - The Globe and Mail
What is Leerink Partnrs’ Estimate for VRDN FY2029 Earnings? - Defense World
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
(VRDN) Long Term Investment Analysis - Stock Traders Daily
Viridian Therapeutics sees stock soar after Phase III TED success - MSN
Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen - MSN
Viridian Therapeutics (NASDAQ:VRDN) Trading Up 6.3%What's Next? - MarketBeat
JPMorgan Chase & Co. Purchases 274,641 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
JPMorgan Chase & Co. Raises Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics (NASDAQ:VRDN) Earns “Buy” Rating from Needham & Company LLC - Defense World
Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - BioSpace
Viridian Therapeutics, Inc. Promotes Seth Harmon to the Role of Chief Financial Officer - Marketscreener.com
(VRDN) Investment Analysis - Stock Traders Daily
Acelyrin To Take Tepezza Competitor Into Phase III In TED - Citeline News & Insights
Viridian Therapeutics (NASDAQ:VRDN) Shares Up 5.8%Here's Why - MarketBeat
Expert Outlook: Viridian Therapeutics Through The Eyes Of 10 Analysts - Benzinga
Viridian Therapeutics (NASDAQ:VRDN) Earns Buy Rating from Needham & Company LLC - MarketBeat
Analysts Set Viridian Therapeutics, Inc. (NASDAQ:VRDN) Price Target at $35.70 - MarketBeat
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Principal Financial Group Inc. Acquires 162,665 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Principal Financial Group Inc. Boosts Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Geode Capital Management LLC Grows Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Geode Capital Management LLC Has $33.98 Million Stock Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - Defense World
Is Viridian Therapeutics, Inc. (NASDAQ:VRDN) Worth US$19.3 Based On Its Intrinsic Value? - Yahoo Finance
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Shares Purchased by Barclays PLC - Defense World
Barclays PLC Boosts Holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN) - MarketBeat
Viridian Therapeutics Inc Stock (VRDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Viridian Therapeutics Inc Stock (VRDN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Mahoney Stephen F. | President and CEO |
Sep 27 '24 |
Buy |
23.33 |
21,400 |
499,262 |
21,400 |
| Fairmount Funds Management LLC | Director |
Sep 13 '24 |
Buy |
18.75 |
1,600,000 |
30,000,000 |
3,445,813 |
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):